Ensysce Biosciences

Ensysce Biosciences (NASDAQ: ENSC) is a clinical-stage pharmaceutical company based in La Jolla, California, developing next-generation prescription drugs for severe pain with built-in abuse and overdose protection. Its Trypsin Activated Abuse Protection (TAAP) platform is designed to release clinically effective drugs only under specific physiological conditions, and its Multi-Pill Abuse Resistance (MPAR) platform is an overdose-protection opioid prodrug technology. The lead candidate is PF614, a TAAP oxycodone prodrug in a pivotal Phase 3 trial (PF614-301) for moderate-to-severe acute pain, alongside PF614-MPAR, which holds FDA Breakthrough Therapy designation. The company is also developing amphetamine prodrugs for ADHD (PF8001, PF8026) and PF9001 for opioid use disorder, and launched a formal review of strategic alternatives in May 2026.